US Stock Insider Trading | Guardant Health disclosed 9 insider transactions on March 17

K-LinePoet · 2026-04-03T08:10:06+00:00

Guardant Health disclosed multiple insider transactions on March 17, 2026, with executives and directors recently selling large amounts of stock. Director Talasaz AmirAli sold 19.4k shares on March 16, involving an amount of up to $1.9817M. The company focuses on advancing oncology through blood testing and data analysis.

K-LinePoet

2026-04-03 08:10:06

Abstract generation in progress

On March 17, 2026, Guardant Health (GH) disclosed nine company insider trading transactions. Director Talasaz AmirAli sold 19,400 shares on March 16, 2026.

【Recent Insider Transactions】

Disclosure Date	Position	Name	Transaction Date	Buy/Sell	Quantity	Price per Share/US$	Total Amount/US$
March 17, 2026	Executive	Saia John G.	March 15, 2026	Sold	4622	85.49	395.1K
March 17, 2026	Executive	EAGLE CRAIG	March 15, 2026	Sold	7661	85.49	654.9K
March 17, 2026	Executive	Kalia Kumud	March 15, 2026	Sold	6839	85.49	584.7K
March 17, 2026	Director	Talasaz AmirAli	January 1, 2026	Sold	1.94万	102.14	1,981.7K
March 17, 2026	Executive	Bell Michael Brian	March 16, 2026	Sold	3000	87.04	261.1K
March 17, 2026	Executive	Bell Michael Brian	March 15, 2026	Sold	7413	85.49	633.7K
March 17, 2026	Director	Talasaz AmirAli	March 13, 2026	Sold	1.37万	85.49	1,168.1K
March 17, 2026	Executive	Freeman Chris	March 15, 2026	Sold	7127	85.49	609.3K
March 17, 2026	Executive	Chudova Darya	March 15, 2026	Sold	5759	85.49	492.3K
March 9, 2026	Director	Hidalgo Medina Manuel	March 6, 2026	Bought	1000	32.55	32.6K

【Company Profile】

Guardant Health, Inc. was incorporated in Delaware in December 2011. The company is a leading precision oncology company, dedicated to helping conquer cancer worldwide by using its proprietary blood tests, large-scale datasets, and advanced analytics. They provide key insights into disease-driving factors by leveraging advanced blood and tissue testing, real-world data, and artificial intelligence analysis, thereby transforming patient care. Their tests help improve treatment outcomes at various stages, including early cancer screening, early cancer recurrence monitoring, and treatment option selection for patients with late-stage cancer.

View Original

This page may contain third-party content, which is provided for information purposes only (not representations/warranties) and should not be considered as an endorsement of its views by Gate, nor as financial or professional advice. See Disclaimer for details.